Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2885242 | 0.90 | EGLN1 (0.43) | EGLN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2887904 | 0.89 | EGLN1 (0.42) | EGLN1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL2888057 | 0.89 | EGLN1 (0.43) | EGLN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2883345 | 0.88 | PTGER4 (0.44) | EGLN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2882107 | 0.86 | SMN1; SMN2 (0.42) | EGLN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2884725 | 0.86 | EGLN1 (0.44) | EGLN1CRHBPCRHR2KDM4EALDH1A1 | |
| SCHEMBL2882521 | 0.85 | EED (0.43) | EGLN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2884003 | 0.85 | EGLN1 (0.40) | EGLN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2887298 | 0.83 | ALDH1A1 (0.49) | EGLN1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL2886519 | 0.82 | EGLN1 (0.45) | EGLN1CRHBPCRHR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3124489-B1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3124489-A1 | THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | Fibrogen, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2016078-B1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN INC (US) | 2016-06-15 | — | — | EP | disclosed |
| US-7696223-B2 | [(2-bromo-4-hydroxy-1-phenyl-1H-pyrrolo[2,3-c]pyridine-5-carbonyl)-amino]-acetic acid; modulates the stability and/or activity of hypoxia inducible factor (HIF) | FIBROGEN, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-2016078-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-01-03 | — | — | US | disclosed |
| WO-2007115315-A2 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS AS HIF MODULATORS | FIBROGEN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004309-A1 | PYRROLO- AND THIAZOLO-PYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885CRHBP 302/4885CRHR2 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.